Document:

Exhibit 4.2

 

NEITHER
THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE ON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT
OR ANY OTHER SECURITIES LAWS (THE “ACTS”). NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK PURCHASABLE HEREUNDER
MAY BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS WARRANT OR
COMMON STOCK PURCHASABLE HEREUNDER, AS APPLICABLE, UNDER THE ACTS, OR (B) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
CORPORATION THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACTS.

 

ICAGEN,
INC.

WARRANT AGREEMENT

 

VOID
AFTER 5:00 P.M. NEW YORK TIME, August __, 2023

 

Issue
Date: August __, 2018

 

1. Basic
Terms. This Warrant Agreement (the “Warrant”) certifies that, for value received, the registered holder specified
below or its registered assigns (“Holder”) is the owner of a warrant of Icagen, Inc., a Delaware corporation having
its principal place of business at 4222 Emperor Blvd., Suite 350, Durham, North Carolina 27703 (the “Corporation”),
subject to adjustments as provided herein, to purchase ___________ (_________) shares of the Common Stock, $.001 par value, of
the Corporation (the “Common Stock”) from the Corporation at the price per share shown below (the “Exercise
Price”).

 

Holder:

 

Exercise
Price per share: $3.50

 

Except
as specifically provided otherwise, all references in this Warrant to the Exercise Price and the number of shares of Common Stock
purchasable hereunder shall be to the Exercise Price and number of shares after any adjustments are made thereto pursuant to this
Warrant.

 

2. Corporation’s
Representations/Covenants. The Corporation represents and covenants that the shares of Common Stock issuable upon the exercise
of this Warrant shall at delivery be fully paid and non-assessable and free from taxes, liens, encumbrances and charges with respect
to their purchase. The Corporation shall take any necessary actions to assure that the par value per share of the Common Stock
is at all times equal to or less than the then current Exercise Price per share of Common Stock issuable pursuant to this Warrant.
The Corporation shall at all times reserve and hold available sufficient shares of Common Stock to satisfy all conversion and
purchase rights of outstanding convertible securities, options and warrants of the Corporation, including this Warrant.

 

3. 
Method of Exercise; Fractional Shares.

 

This
Warrant is exercisable at the option of the Holder at any time by surrendering this Warrant, on any business day during the period
(the “Exercise Period”) beginning the business day after the issue date of this Warrant specified above and ending
at 5:00 p.m. (New York time) five (5) years after the Issue Date. To exercise this Warrant, the Holder shall surrender this Warrant
at the principal office of the Corporation or that of the duly authorized and acting transfer agent for its Common Stock, together
with the executed exercise form (substantially in the form of that attached hereto) and together with payment for the Common Stock
purchased under this Warrant The principal office of the Corporation is located at the address specified in Section 1 of this
Warrant; provided, however, that the Corporation may change its principal office upon notice to the Holder. Payment
shall be made by check payable to the order of the Corporation or by wire transfer. This Warrant is not exercisable with respect
to a fraction of a share of Common Stock. In lieu of issuing a fraction of a share remaining after exercise of this Warrant as
to all full shares covered by this Warrant, the Corporation shall either at its option (a) pay for the fractional share cash equal
to the same fraction at the fair market price for such share; or (b) issue scrip for the fraction in the registered or bearer
form which shall entitle the Holder to receive a certificate for a full share of Common Stock on surrender of scrip aggregating
a full share.

 

     

     

    

 

4. 
Protection Against Dilution.

 

If
the Corporation, with respect to the Common Stock, (1) pays a dividend or makes a distribution on shares of Common Stock that
is paid in shares of Common Stock or in securities convertible into or exchangeable for Common Stock (in which latter event the
number of shares of Common Stock initially issuable upon the conversion or exchange of such securities shall be deemed to have
been distributed), (2) subdivides outstanding shares of Common Stock, (3) combines outstanding shares of Common Stock into a smaller
number of shares, or (4) issues by reclassification of Common Stock any shares of capital stock of the Corporation, the Exercise
Price in effect immediately prior thereto shall be adjusted so that each Holder thereafter shall be entitled to receive the number
and kind of shares of Common Stock or other capital stock of the Corporation that it would have owned or been entitled to receive
in respect of this Warrant immediately after the happening of any of the events described above had this Warrant been converted
immediately prior to the happening of that event. An adjustment made in accordance with this section shall become effective immediately
after the record date, in the case of a dividend, and shall become effective immediately after the effective date, in the case
of a subdivision, combination, or reclassification. If, as a result of an adjustment made in accordance with this Section 4, the
Holder becomes entitled to receive shares of two or more classes of capital stock or shares of Common Stock and other capital
stock of the Corporation, the board of directors (whose determination shall be conclusive) shall determine the allocation of the
adjusted Exercise Rate between or among shares of such classes of capital stock or shares of Common Stock and other capital stock.

 

5. 
Adjustment for Reorganization, Consolidation, Merger.

 

In
the event of any consolidation or merger to which the Corporation is a party other than a consolidation or merger in which the
Corporation is the continuing corporation, or the sale or conveyance to another corporation of the property of the Corporation
as an entirety or substantially as an entirety or any statutory exchange of securities with another corporation (including any
exchange effected in connection with a merger of a third corporation into the Corporation) (each such transaction referred to
herein as “Reorganization”), no adjustment of exercise rights or the Exercise Price shall be made; provided,
however, the Holder shall thereupon be entitled to receive if the Holder chooses to exercise the Warrant within ten days
of the notice of the Reorganization and provision shall be made therefor in any agreement relating to a Reorganization, the kind
and number of securities or property (including cash) of the corporation resulting from such consolidation or surviving such merger
or to which such properties and assets shall have been sold or otherwise transferred or with whom securities have been exchanged,
which the Holder would have owned or been entitled to receive as a result of such Reorganization had this Warrant been exercised
immediately prior to such Reorganization (and assuming the Holder failed to make an election, if any was available, as to the
kind or amount of securities, property or cash receivable by reason of such Reorganization; provided that if the kind or amount
of securities, property or cash receivable upon such Reorganization is not the same for each share of Common Stock in respect
of which such rights of election shall not have been exercised (“non electing share”) then for the purpose of this
section the kind and amount of securities, property or cash receivable upon such Reorganization for each non electing share shall
be deemed to be the kind and amount so receivable per share by a plurality of the non electing shares). In any case, appropriate
adjustment shall be made in the application of the provisions herein set forth with respect to the rights and interests thereafter
of the Holder, to the end that the provisions set forth herein (including the specified changes and other adjustments to the conversion
rate) shall thereafter be applicable, as nearly as reasonably may be, in relation to any shares, other securities or property
thereafter receivable upon exercise of this Warrant. The provisions of this section similarly apply to successive Reorganizations.

 

6. 
Notice of Adjustment. On the happening of an event requiring an adjustment of the Exercise Price or the shares purchasable
under this Warrant, the Corporation shall, within thirty (30) business days, give written notice to the Holder stating the adjusted
Exercise Price and the adjusted number and kind of securities or other property purchasable under this Warrant resulting from
the event and setting forth in reasonable detail the method of calculation and the facts upon which the calculation is based.

 

7. 
Dissolution, Liquidation. In case of the voluntary or involuntary dissolution, liquidation or winding up of the Corporation
(other than in connection with reorganization, consolidation, merger, or other transaction covered by paragraph 5 above) is at
any time proposed; the Corporation shall give at least thirty days prior written notice to the Holder. Such notice shall contain:
(a) the date on which the transaction is to take place; (b) the record date (which shall be at least thirty (30) days after the
giving of the notice) as of which holders of Common Stock will be entitled to receive distributions as a result of the transaction;
(c) a brief description of the transaction, (d) a brief description of the distributions to be made to holders of Common Stock
as a result of the transaction; and (e) an estimate of the fair value of the distributions. On the date of the transaction, if
it actually occurs, this Warrant and all rights under this Warrant shall terminate.

 

    	 	2	 

     

    

 

8. 
Rights of Holder. The Corporation shall deliver to the Holder all notices and other information provided to its holders
of shares of Common Stock or other securities which may be issuable hereunder concurrently with the delivery of such information
to the holders. This Warrant does not entitle the Holder to any voting rights or, except for the foregoing notice provisions,
any other rights as a shareholder of the Corporation. No dividends are payable or will accrue on this Warrant or the shares of
Common Stock purchasable under this Warrant until, and except to the extent that, this Warrant is exercised. Upon the surrender
of this Warrant and payment of the Exercise Price as provided above, the person or entity entitled to receive the shares of Common
Stock issuable upon such exercise shall be treated for all purposes as the record holder of such shares as of the close of business
on the date of the surrender of this Warrant for exercise as provided above. Upon the exercise of this Warrant, the Holder shall
have all of the rights of a shareholder in the Corporation.

 

9. 
Exchange for Other Denominations. This Warrant is exchangeable, on its surrender by the Holder to the Corporation, for
a new Warrant of like tenor and date representing in the aggregate the right to purchase the balance of the number of shares purchasable
under this Warrant in denominations and subject to restrictions on transfer contained herein, in the names designated by the Holder
at the time of surrender.

 

10. Substitution.
Upon receipt by the Corporation of evidence satisfactory (in the exercise of reasonable discretion) to it of the ownership of
and the loss, theft or destruction or mutilation of the Warrant, and (in the case or loss, theft or destruction) of indemnity
satisfactory (in the exercise of reasonable discretion) to it, and (in the case of mutilation) upon the surrender and cancellation
thereof, the Corporation will issue and deliver, in lieu thereof, a new Warrant of like tenor.

 

11. Restrictions
on Transfer. Neither this Warrant nor the shares of Common Stock issuable on exercise of this Warrant have been registered
under the Securities Act or any other securities laws (the “Acts”). Neither this Warrant nor the shares of Common
Stock purchasable hereunder may be sold, transferred, pledged or hypothecated in the absence of (a) an effective registration
statement for this Warrant or Common Stock purchasable hereunder, as applicable, under the Acts, or (b) an opinion of counsel
reasonably satisfactory to the Corporation that registration is not required under such Acts. If the Holder seeks an opinion as
to transfer without registration from Holder’s counsel, the Corporation shall provide such factual information to Holder’s
counsel as Holder’s counsel reasonably requests for the purpose of rendering such opinion. Each certificate evidencing shares
of Common Stock purchased hereunder will bear a legend describing the restrictions on transfer contained in this paragraph unless,
in the opinion of counsel reasonably acceptable to the Corporation, the shares need no longer to be subject to the transfer restrictions.

 

12. Transfer.
Except as otherwise provided in this Warrant, this Warrant is transferable only on the books of the Corporation by the Holder
in person or by attorney, on surrender of this Warrant, properly endorsed.

 

13. Recognition
of Holder. Prior to due presentment for registration of transfer of this Warrant, the Corporation shall treat the Holder as
the person exclusively entitled to receive notices and otherwise to exercise rights under this Warrant. All notices required or
permitted to be given to the Holder shall be in writing and shall be given by first class mail, postage prepaid, addressed to
the Holder at the address of the Holder appearing in the records of the Corporation.

 

14. Payment
of Taxes. The Corporation shall pay all taxes and other governmental charges, other than applicable income taxes, that may
be imposed with respect to the issuance of shares of Common Stock pursuant to the exercise of this Warrant.

 

15.
 Headings. The headings in this Warrant are for purposes of convenience in reference only, shall not be deemed to
constitute a part of this Warrant and shall not affect the meaning or construction of any of the provisions of this Warrant.

 

16. Miscellaneous.
This Warrant may not be changed, waived, discharged or terminated except by an instrument in writing signed by the Corporation
and the Holder. This Warrant shall inure to the benefit of and shall be binding upon the successors and assigns of the Corporation.
Under no circumstances may this Warrant be assigned by the Holder.

 

17. Governing
Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York without giving effect
to its principles governing conflicts of law.

 

	 	ICAGEN,
    INC. 
	 	 	 
	 	By:	 
	 	Name: 	Richard Cunningham
	 	Title:	Chief Executive Officer

 

    	 	3	 

     

    

 

ICAGEN,
INC.

Form of Transfer

 

(To
be executed by the Holder to transfer the Warrant)

 

For
value received the undersigned registered holder of the attached Warrant hereby sells, assigns, and transfers the Warrant to the
Assignee(s) named below:

 

	Names
    of Assignee	 	Address	 	Taxpayer
    ID No.	 	Number
    of Shares subject to transferred Warrant
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

The
undersigned registered holder further irrevocably appoints _____________________________ _____________________________________
attorney (with full power of substitution) to transfer this Warrant as aforesaid on the books of the Corporation.

 

	Date:	 	 	 
	 	 	 	Signature

 

    	 	4	 

     

    

 

ICAGEN,
INC.

Exercise Form

 

(To
be executed by the Holder to purchase Common Stock pursuant to the Warrant)

 

The
undersigned holder of the attached Warrant hereby irrevocably elects to exercise purchase rights represented by such Warrant for,
and to purchase, ___________ shares of Common Stock of Icagen, Inc., a Delaware corporation for the cash payment for those shares.

 

The
undersigned requests that (1) a certificate for the shares be issued in the name of the undersigned and (2) if the number of shares
with respect to which the undersigned holder has exercised purchase rights is not all of the shares purchasable under this Warrant,
that a new Warrant of like tenor for the balance of the remaining shares purchasable under this Warrant be issued.

 

	Date:	 	 	 
	 	 	 	Signature

 

 

5Exhibit 10.1

 

ICAGEN,
INC.

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of August , 2018, by and between
Icagen, Inc., a Delaware corporation (the “Company”), and the investors set forth on the signature pages affixed
hereto (each, an “Investor” and, collectively, the “Investors”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to exemptions from registration under the Securities
Act (as defined below), the Company desires to issue and sell to each Investor, and each Investor, severally and not jointly,
desires to purchase from the Company, Units (as defined below) of the Company, as more fully described in this Agreement;

 

WHEREAS,
the Investors wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms
and conditions stated in this Agreement, on a “best efforts” basis up to a maximum of 150 Units, each Unit consisting
of (i) the Company’s 10% Subordinated Promissory Note in the principal amount of $10,000 due on the earlier of (x) the date
that is twelve (12) months after the Issue Date or (y) the Company’s receipt of the proceeds of funding from its next collaboration/partnership
(the “Note”) and (ii) a five year warrant to purchase 1,500 shares of Common Stock of the Company, par value
$0.001, (the “Common Stock”) for each $10,000 Note investment (the “Common Stock”) of the
Company at an exercise price of $3.50 per share. (the Note and the Warrants being hereinafter referred to as the “Units”
or “Securities”), upon the terms and conditions set forth in this Agreement; and

 

WHEREAS,
in connection with the Investors’ purchase of the Units, the Investors will be subject to certain restrictions on the
transfer of the Securities, all as more fully set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual terms, conditions and other agreements set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties
hereto hereby agree to the sale and purchase of the Units as set forth herein.

 

1. Definitions.

 

For
purposes of this Agreement, the terms set forth below shall have the corresponding meanings provided below.

 

“Affiliate”
shall mean, with respect to any specified Person (as defined below), (i) if such Person is an individual, the spouse, heirs, executors,
or legal representatives of such individual, or any trusts for the benefit of such individual or such individual’s spouse
and/or lineal descendants, or (ii) otherwise, another Person that directly, or indirectly through one or more intermediaries,
controls, is controlled by, or is under common control with, the Person specified. As used in this definition, “control”
shall mean the possession, directly or indirectly, of the sole and unilateral power to cause the direction of the management and
policies of a Person, whether through the ownership of voting securities or by contract or other written instrument.

 

“Business
Day” shall mean any day on which banks located in New York City are not required or authorized by law to remain closed.

 

“Closing”
and “Closing Date” as defined in Section 2.2 (c) hereof.

 

“Common
Stock” as defined in the recitals above.

 

     

     

    

 

“Company
Financial Statements” as defined in Section 4.5(a) hereof.

 

“Company’s
Knowledge” means the actual knowledge of the Chief Executive Officer (as defined in Rule 405 under the Securities Act),
or the knowledge of any fact or matter which the Chief Executive Officer would reasonably be expected to become aware of in the
course of performing the duties and responsibilities.

 

“Company
Permits” as defined in Section 4.6 hereof.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“First
Closing” and “First Closing Date” as defined in Section 2.2(a) hereof.

 

“Intellectual
Property Rights” as defined in Section 4.13 hereof.

 

“Liens”
means any mortgage, lien, title claim, assignment, encumbrance, security interest, adverse claim, contract of sale, restriction
on use or transfer or other defect of title of any kind.

 

“Material
Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial
or otherwise), business, or prospects of the Company; (ii) the transactions contemplated hereby or in any of the Transaction Documents;
or (iii) the ability of the Company to perform its obligations under the Transaction Documents (as defined below).

 

“Person”
shall mean an individual, entity, corporation, partnership, association, limited liability company, limited liability partnership,
joint-stock company, trust or unincorporated organization.

 

“Purchase
Price” shall mean up to $10,000.

 

“Regulation
D” as defined in Section 3.7 hereof.

 

“Regulation
S” as defined in Section 6.1(i)(E) hereof.

 

“Rule
144” means Rule 144 promulgated under the Securities Act (or a successor rule).

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“SEC
Documents” as defined in Section 4.5 hereof.

 

“Securities”
as defined in the recitals above.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Subsequent
Closing” and “Subsequent Closing Date” as defined in Section 2.2(b) hereof.

 

“Subsidiaries”
shall mean any corporation or other entity or organization, whether incorporated or unincorporated, in which the Company owns,
directly or indirectly, any equity or other ownership interest or otherwise controls through contract or otherwise.

 

“Transaction
Documents” shall mean this Agreement, the Note and the Warrant.

 

“Transfer”
shall mean any sale, transfer, assignment, conveyance, charge, pledge, mortgage, encumbrance, hypothecation, security interest
or other disposition, or to make or effect any of the above.

 

    2

     

    

 

“Units”
as defined in the recitals above.

 

“Warrant”
as defined in the recitals above.

 

2. Sale
and Purchase of Securities.

 

2.1. Subscription
for Units by Investors. Subject to the terms and conditions of this Agreement, on the Closing Date (as hereinafter defined)
each of the Investors shall severally, and not jointly, purchase, and the Company shall sell and issue to the Investors, the Units,
in the respective amounts set forth on the signature pages attached hereto in exchange for the Purchase Price.

 

2.2 Closings.

 

(a) First
Closing. Subject to the terms and conditions set forth in this Agreement, the Company shall issue and sell to each Investor,
and each Investor shall, severally and not jointly, purchase from the Company on the First Closing Date, such number of Units
set forth on the signature pages attached hereto, which will be reflected opposite such Investor’s name on Exhibit A-1
(the “First Closing”). The date of the First Closing is hereinafter referred to as the “First
Closing Date.”

 

(b)
 Subsequent Closing(s). The Company agrees to issue and sell to each Investor
listed on the Subsequent Closing Schedule of Investors, and each such Investor agrees, severally and not jointly, to purchase
from the Company on such Subsequent Closing Date such number of Units set forth on the signature pages attached hereto, which
will be reflected opposite such Investor’s name on Exhibit A-2 (a “Subsequent Closing”). There
may be more than one Subsequent Closing; provided, however, that the final Subsequent Closing shall take place within
the time periods determined by the Company. The date of any Subsequent Closing is hereinafter referred to as a “Subsequent
Closing Date.” Notwithstanding the foregoing, the maximum number of Units to be sold at the First Closing and all Subsequent
Closings shall not exceed 150 in the aggregate.

 

(c) Closing.
The First Closing and any applicable Subsequent Closings are each referred to in this Agreement as a “Closing.”
The First Closing Date and any Subsequent Closing Dates are sometimes referred to herein as a “Closing Date.”
All Closings shall occur at the offices of Gracin & Marlow, LLP., counsel to the Company, at The Chrysler Building, 405 Lexington
Avenue, New York, New York 10174 or remotely via the exchange of documents and signatures.

 

2.3.
 Closing Deliveries. At each Closing, the Company shall deliver to the Investors,
against delivery by the Investor of the Purchase Price (as provided below), a Note and a Warrant. At each Closing, each Investor
shall deliver or cause to be delivered to the Company the Purchase Price set forth in its counterpart signature page annexed hereto
by paying United States dollars via bank, certified or personal check which has cleared prior to the applicable Closing Date or
in immediately available funds, by wire transfer to the following account:

 

Bank
Name: JP Morgan Chase Bank N.A

Bank
Address: 5950 Glades Road, Boca Raton, Florida, 33431

Routing
number: 267084131

Account
name: Icagen Inc.

Account
number:672002107

 

    3

     

    

 

3. Representations,
Warranties and Acknowledgments of the Investors.

 

Each
Investor, severally and not jointly, represents and warrants to the Company solely as to such Investor that:

 

3.1 Authorization.
The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor is a party have been
duly authorized and will each constitute the valid and legally binding obligation of such Investor, enforceable against such Investor
in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting creditors’ rights generally.

 

3.2 Purchase
Entirely for Own Account. The Securities to be received by such Investor hereunder will be acquired for such Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the
Securities Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same in violation of the Securities Act, without prejudice, however, to such Investor’s right at all times to
sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws.
Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period
of time. Such Investor is not a broker-dealer registered with the SEC under the Exchange Act or an entity engaged in a business
that would require it to be so registered.

 

3.3. Investment
Experience. Such Investor acknowledges that the purchase of the Securities is a highly speculative investment and that it
can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial
or business matters such that it is capable of evaluating the merits and risks of the investment contemplated hereby.

 

3.4
 Disclosure of Information. Such Investor has had an opportunity to receive all
information related to the Company and the Securities requested by it and to ask questions of and receive answers from the Company
regarding the Company, its business and the terms and conditions of the offering of the Units. Neither such inquiries nor any
other due diligence investigation conducted by such Investor shall modify, amend or affect such Investor’s right to rely
on the Company’s representations and warranties contained in this Agreement. Such Investor acknowledges that it has received
and reviewed the Company’s filings with the SEC and the Transaction Documents.

 

3.5 Restricted
Securities. Such Investor understands that the Units, and the components thereof, are characterized as “restricted securities”
under the U.S. federal securities laws since they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities
Act only in certain limited circumstances.

 

3.6 Legends.
It is understood that, except as provided below, certificates evidencing the Securities may bear the following or any similar
legend:

 

(a) “The
securities represented hereby may not be transferred unless (i) such securities have been registered for sale pursuant to the
Securities Act of 1933, as amended; (ii) such securities may be sold pursuant to an available exemption from, or in a transaction
not subject to, the registration requirements of the Securities Act; or (iii) the Company has received an opinion of counsel reasonably
satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933 or qualification
under applicable state securities laws.”

 

(b) If
required by the authorities of any state in connection with the issuance of sale of the Securities, the legend required by such
state authority.

 

3.7 Accredited
Investor/ Bad Boy Acts. Such Investor, and if an entity, all equity holders of such Investor, is an accredited investor as
defined in Rule 501(a) of Regulation D, as amended, under the Securities Act (“Regulation D”). Such Investor
has not been the subject of any bad actor events under Rule 506 of Regulation D.

 

3.8 No
General Solicitation. Such Investor did not learn of the investment in the Securities as a result of any public advertising
or general solicitation.

 

    4

     

    

 

3.9
 Brokers and Finders. No Investor will have, as a result of the transactions contemplated
by the Transaction Documents, any valid right, interest or claim against or upon the Company, any Subsidiary or any other Investor,
for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf
of such Investor.

 

4.
 Representations and Warranties of the Company.

 

The
Company represents, warrants and covenants to the Investors that:

 

4.1. Organization;
Execution, Delivery and Performance.

 

(a) The
Company is a corporation or other entity duly organized, validly existing and in good standing under the laws of the jurisdiction
in which it is incorporated or organized, with full power and authority (corporate and other) to own, lease, use and operate its
properties and to carry on its business as and where now owned, leased, used, operated and conducted. The Company is duly qualified
as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership or use of property
or the nature of the business conducted by it makes such qualification necessary except where the failure to be so qualified or
in good standing would not have a Material Adverse Effect.

 

(b)(i)The
Company has all requisite corporate power and authority to enter into and perform the Transaction Documents and to consummate
the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof;
(ii) the execution and delivery of the Transaction Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including without limitation, the issuance of the Securities) have been duly authorized by the
Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its stockholders,
is required; (iii) each of the Transaction Documents has been duly executed and delivered by the Company by its authorized representative,
and such authorized representative is a true and official representative with authority to sign each such document and the other
documents or certificates executed in connection herewith and bind the Company accordingly; and (iv) each of the Transaction Documents
constitutes, and upon execution and delivery thereof by the Company will constitute, a legal, valid and binding obligation of
the Company enforceable against the Company in accordance with its terms, except to the extent limited by applicable bankruptcy,
insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights and
general principles of equity that restrict the availability of equitable or legal remedies.

 

4.2.
 Securities Duly Authorized. The Notes to be issued to each such Investor pursuant
to this Agreement, when issued and delivered in accordance with the terms of this Agreement, will be duly and validly issued free
from all taxes or Liens with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights
of stockholders of the Company. The Warrants to be issued to each such Investor, when issued in accordance with the terms of this
Agreement, will be legal, valid and binding obligations of the Company enforceable in accordance with their terms. The shares
of Common Stock issuable upon exercise of the Warrants in accordance with their respective terms will be duly and validly issued
and fully paid and non-assessable. Subject to the accuracy of the representations and warranties of the Investors to this Agreement,
the offer and issuance by the Company of the Securities is exempt from registration under the Securities Act.

 

    5

     

    

 

4.3 No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby will not: (i) conflict with or result in a violation of any provision
of the Certificate of Incorporation or By-laws of the Company; or (ii) violate or conflict with, or result in a breach of any
provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent
license or instrument to which the Company or any of its Subsidiaries is a party, except for possible violations, conflicts or
defaults as would not, individually or in the aggregate, have a Material Adverse Effect; or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations
of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected. Neither the Company
nor any of its Subsidiaries is in default (and no event has occurred which with notice or lapse of time or both could put the
Company or any of its Subsidiaries in default) under, and neither the Company nor any of its Subsidiaries has taken any action
or failed to take any action that would give to others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party or by which any property or
assets of the Company or any of its Subsidiaries is bound or affected, or for possible defaults as would not, individually or
in the aggregate, have a Material Adverse Effect. The businesses of the Company and its Subsidiaries are not being conducted in
violation of any law, rule ordinance or regulation of any governmental entity, except for possible violations which would not,
individually or in the aggregate, have a Material Adverse Effect. Except as required under the Securities Act, the Exchange Act,
and any applicable state securities laws, the Company is not required to obtain any consent, authorization or order of, or make
any filing or registration with, any court, governmental agency, regulatory agency, self regulatory organization or stock market
or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement or to issue and
sell the Securities in accordance with the terms hereof. All consents, authorizations, orders, filings and registrations which
the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof.

 

4.4. Capitalization.
As of August 1, 2018, the authorized capital stock of the Company consists of (i) 50,000,000 shares of Common Stock, of which
6,393,107 shares are outstanding, 10,000,000 shares of Preferred Stock, of which 400,000 are designated Series A Preferred Stock
and no shares are issued and outstanding, 3,000,000 shares are designated Series B Preferred Stock and no shares are issued and
outstanding, 1,142,856 are designated as Series C Preferred Stock, of which 714,275 are issued and outstanding, 3,819,059 of the
authorized shares are reserved for the issuance of warrants, and 1,382,945 options have been issued to employees, consultants
and directors of Icagen, Inc. In the Offering contemplated by this Agreement, warrants exercisable for up to 225,000 shares of
Common Stock may be issued to investors. The Company has reserved, and at all times will keep reserved, a sufficient number of
shares for issuance upon the conversion of the Notes and the exercise of the Warrants. Except as described in the SEC Documents,
(i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements,
understandings, claims or other commitments or rights of any character whatsoever relating to, or securities or rights convertible
into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company
or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries;
(ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale
of any of its or their securities under the Securities Act (except for the registration rights provisions contained herein and
piggyback rights of the Series A Preferred Stock) that will be triggered by the issuance of the Securities. All of such outstanding
shares of capital stock are, or upon issuance will be, duly authorized, validly issued, fully paid and nonassessable. No shares
of capital stock of the Company are subject to preemptive rights or any other similar rights of the stockholders of the Company
or any Lien imposed through the actions or failure to act of the Company.

 

    6

     

    

 

4.5. SEC
Information.

 

(a) The
Company has filed or furnished all registration statements, prospectuses, reports, schedules, forms, statements and other documents
required to be filed or furnished by it with the SEC pursuant to the requirements of the Securities Act or the Exchange Act (all
of the foregoing and all other documents filed with the SEC prior to the date hereof, being hereinafter referred to herein as
the “SEC Documents”). The SEC Documents have been made available to the Investors via the SEC’s EDGAR
system. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Exchange
Act or the Securities Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable to the
SEC Documents, and none of the SEC Documents, including any financial statements, schedules or exhibits included or incorporated
by reference therein, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to
state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. There are no outstanding any unresolved comments of the staff of the SEC. As of their
respective dates, the financial statements of the Company included in the SEC Documents (“Company Financial Statements”)
complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto. The Company Financial Statements have been prepared in accordance with United States generally accepted
accounting principles (“GAAP”), consistently applied, during the periods involved (except (i) as may be otherwise
indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent
they may not include footnotes or may be condensed or summary statements in accordance with GAAP and the applicable rules and
regulations of the SEC) and fairly present in all material respects the consolidated financial position of the Company and its
consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments as permitted by GAAP and the applicable
rules and regulations of the SEC). Except as set forth in the Company Financial Statements, the Company has no liabilities, contingent
or otherwise, other than: (i) liabilities incurred in the ordinary course of business subsequent to March 31, 2018 (the fiscal
period end of the Company’s most recently-filed periodic report) and (ii) obligations under contracts and commitments incurred
in the ordinary course of business and not required under generally accepted accounting principles to be reflected in such financial
statements, which, individually or in the aggregate, are not material to the financial condition or operating results of the Company.

 

(b) The
shares of Common Stock are not currently traded on any market.

 

4.6 Permits;
Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations, licenses,
permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its
properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”),
and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of
the Company Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of
the Company Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. Since March 31, 2018, neither the Company nor any of its Subsidiaries
has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices
relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse
Effect.

 

4.7
 Litigation. Except as set forth in the SEC Documents, there is no action, suit,
claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization
or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company or
any of its Subsidiaries, or their respective businesses, properties or assets or their officers or directors in their capacity
as such, that would have a Material Adverse Effect. The Company is unaware of any facts or circumstances which might give rise
to any of the foregoing. There has not been, and to the Company’s Knowledge, there is not pending or contemplated, any investigation
by the SEC involving the Company, any of its Subsidiaries or any current or former director or executive officer of the Company
or any of its Subsidiaries.

 

    7

     

    

 

4.8 No
Material Changes.

 

(a) Since
March 31, 2018, except as set forth in the SEC Documents, there has not been:

 

(i) Any
material adverse change in the financial condition, operations or business of the Company from that shown on the Company Financial
Statements, or any material transaction or commitment effected or entered into by the Company outside of the ordinary course of
business;

 

(ii) Any
effect, change or circumstance which has had, or could reasonably be expected to have, a Material Adverse Effect; or

 

(iii) Any
incurrence of any material liability outside of the ordinary course of business.

 

4.9
 No General Solicitation. Neither the Company nor any person participating on
the Company’s behalf in the transactions contemplated hereby has conducted any “general solicitation,” as such
term is defined in Regulation D promulgated under the Securities Act, with respect to any of the Securities being offered hereby.

 

4.10
 No Integrated Offering. Neither the Company, nor any of its Affiliates, nor any
person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers
to buy any security under circumstances that would require registration under the Securities Act of the issuance of the Securities
to the Investors. The issuance of the Securities to the Investors will not be integrated with any other issuance of the Company’s
securities (past, current or future) for purposes of any stockholder approval provisions applicable to the Company or its securities.

 

4.11 No
Brokers. Except as set forth below, the Company has taken no action which would give rise to any claim by any person for brokerage
commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby.

 

4.12 Form
D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Securities as required under Regulation D within
ten days after the First Closing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably
determine is necessary to qualify the Securities for sale to the Investors at the applicable Closing pursuant to this Agreement
under applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from
such qualification).

 

4.13 Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade
names, service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (“Intellectual Property Rights”) necessary to conduct their respective
businesses as now conducted and as presently proposed to be conducted. None of the Company’s or its Subsidiaries’
Intellectual Property Rights have expired, terminated or been abandoned, or are expected to expire, terminate or be abandoned,
within two years from the date of this Agreement. The Company has no knowledge of any infringement by the Company or any of its
Subsidiaries of Intellectual Property Rights of others. Except as set forth in the SEC Documents, there is no claim, action or
proceeding being made or brought, or to the Company’s Knowledge, being threatened, against the Company or any of its Subsidiaries
regarding their Intellectual Property Rights. The Company is not aware of any facts or circumstances which might give rise to
any of the foregoing infringements or claims, actions or proceedings. The Company and each of its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where
failure to take such measures would not, either individually or in the aggregate, reasonably be expected to result in a Material
Adverse Effect.

 

    8

     

    

 

4.14 Tax
Status. Except for occurrences that would not, either individually or in the aggregate, reasonably be expected to result in
a Material Adverse Effect, the Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state
income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject; (ii) has timely
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith; and (iii) has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the
officers of the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner
as to qualify as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as
amended.

 

4.15 Shell
Company Status. The Company was never a “shell issuer”, as defined in Rule 144(i)(1).

 

4.16 Investment
Company Act Status. The Company and its subsidiaries are not, and after giving effect to the offering and sale of the Units
will not be, required to register as an “investment company” as such term is defined in the Investment Company Act
of 1940, as amended.

 

5. Transfer
Restrictions.

 

5.1. Transfer
or Resale. Each Investor understands that:

 

The
sale or resale of all or any portion of the Securities has not been and is not being registered under the Securities Act or any
applicable state securities laws, and all or any portion of the Securities may not be transferred unless:

 

(1)
 the Securities are sold pursuant to an effective registration statement under the Securities
Act;

 

(2) the
Investor shall have delivered to the Company, at the cost of the Company, a customary opinion of counsel that shall be in form,
substance and scope reasonably acceptable to the Company, to the effect that the Securities to be sold or transferred may be sold
or transferred pursuant to an exemption from such registration;

 

(3)
 the Securities are sold or transferred to an “affiliate” (as defined
in Rule 144) of the Investor who agrees to sell or otherwise transfer the Securities only in accordance with this Section 6.1
and who is an Accredited Investor;

 

(4)
 the Securities are sold pursuant to Rule 144; or

 

(5)
 the Securities are sold pursuant to Regulation S under the Securities Act (or a successor
rule) (“Regulation S”);

 

and,
in each case, the Investor shall have delivered to the Company, at the cost of the Company, a customary opinion of counsel, in
form, substance and scope reasonably acceptable to the Company. Notwithstanding the foregoing or anything else contained herein
to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account or other lending
arrangement.

 

    9

     

    

 

5.2
 Transfer Agent Instructions. If an Investor provides the Company with a customary
opinion of counsel, that shall be in form, substance and scope reasonably acceptable to the Company, to the effect that a public
sale or transfer of such Securities may be made without registration under the Securities Act and such sale or transfer is effected,
the Company shall permit the transfer and promptly instruct its transfer agent to issue one or more certificates, free from restrictive
legend, in such name and in such denominations as specified by such Investor. The Company acknowledges that a breach by it of
its obligations hereunder will cause irreparable harm to the Investors, by vitiating the intent and purpose of the transactions
contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section
5.2 may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section,
that the Investors shall be entitled, in addition to all other available remedies, to an injunction restraining any breach and
requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security being required.

 

6. Conditions
to Closing of the Investors.

 

The
obligation of each Investor hereunder to purchase the Securities at the Closing is subject to the satisfaction, at or before the
Closing Date, of each of the following conditions, provided that these conditions are for each Investor’s sole benefit and
may be waived by such Investor at any time in its sole discretion by providing the Company with prior written notice thereof:

 

6.1
 Representations, Warranties and Covenants. The representations and warranties
of the Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though
originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true
and correct in all material respects as of such date) and the Company shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Company at
or prior to the Closing Date.

 

6.2 Consents.
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the
sale of the Securities.

 

6.3
 Delivery by Company. The Company shall have duly executed and delivered to each
Investor each of the other Transaction Documents.

 

6.4
 No Material Adverse Effect. Since the date of first execution of this Agreement,
no event or series of events shall have occurred that reasonably would have or result in a Material Adverse Effect.

 

6.5 No
Prohibition. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any
of the transactions contemplated by the Transaction Documents.

 

6.6
 Other Documents. The Company shall have delivered to such Investor such other
documents, instruments or certificates relating to the transactions contemplated by this Agreement as such Investor or its counsel
may reasonably request.

 

7.
 Conditions to Closing of the Company.

 

The
obligations of the Company to effect the transactions contemplated by this Agreement with each Investor are subject to the fulfillment
at or prior to each Closing Date of the conditions listed below.

 

    10

     

    

 

7.1.
 Representations and Warranties. The representations and warranties made by such
Investor in Section 3 shall be true and correct in all material respects at the time of Closing as if made on and as of such date.

 

7.2 Corporate
Proceedings. All corporate and other proceedings required to be undertaken by such Investor in connection with the transactions
contemplated hereby shall have occurred and all documents and instruments incident to such proceedings shall be reasonably satisfactory
in substance and form to the Company.

 

7.3 Delivery
by the Investor. The Investor shall have duly executed and delivered to each Investor (a) each of the other Transaction Documents
to be signed by the Investor and (b) a Purchaser Questionnaire and a Purchaser Information Request.

 

8. Miscellaneous.

 

8.1. Notices.
All notices, requests, demands and other communications provided in connection with this Agreement shall be in writing and shall
be deemed to have been duly given at the time when hand delivered, delivered by express courier, or sent by facsimile (with receipt
confirmed by the sender’s transmitting device) in accordance with the contact information provided below or such other contact
information as the parties may have duly provided by notice.

 

	The
        Company: 

         

        Icagen,
Inc.

4222 Emperor Blvd., Suite 350

Durham, North Carolina 27703

Telephone: (919) 941-5206

        Facsimile:
        (302) 347-1326

        Attention: Mark Korb

                         Chief Financial Officer
	With
        a copy to:

         

        Gracin
& Marlow, LLP

        The
Chrysler Building

        405
Lexington Avenue, 26th Floor

        New
York, New York 10174

        Attention:
Leslie Marlow, Esq.

        Telephone:
(212) 907-6457

        Facsimile:
(212) 208-4657

	 

                                                                                                 The
        Investors:

         

        As
        per the contact information provided on the signature pages hereof.

 

8.2
 Survival of Representations and Warranties. Each party hereto covenants and agrees
that the representations and warranties of such party contained in this Agreement shall survive the Closing. Each Investor shall
be responsible only for its own representations, warranties, agreements and covenants hereunder.

 

8.3 Indemnification.

 

(a)
 The Company agrees to indemnify and hold harmless each Investor and its Affiliates and
their respective directors, officers, employees and agents from and against any and all losses, claims, damages, liabilities and
expenses (including without limitation reasonable attorney fees and disbursements and other expenses incurred in connection with
investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof)
(collectively, “Losses”) to which such Person may become subject as a result of any breach of representation,
warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Documents, and will
reimburse any such Person for all such amounts as they are incurred by such Person.

 

    11

     

    

 

(b)
 Promptly after receipt by any Investor (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to this Section 8.4, such Indemnified Person shall promptly
notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably
satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses; provided, however,
that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is materially prejudiced by such failure to notify. In any such proceeding, any Indemnified
Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel;
or (ii) in the reasonable judgment of counsel to such Indemnified Person representation of both parties by the same counsel would
be inappropriate due to actual or potential differing interests between them. The Company shall not be liable for any settlement
of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, but if settled with
such consent, or if there be a final judgment for the plaintiff, the Company shall indemnify and hold harmless such Indemnified
Person from and against any loss or liability (to the extent stated above) by reason of such settlement or judgment. Without the
prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, the Company shall not affect
any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party
and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release
of such Indemnified Person from all liability arising out of such proceeding.

 

8.4 Entire
Agreement. This Agreement contains the entire agreement between the parties hereto in respect of the subject matter contained
herein and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter
contained herein.

 

8.5 Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns only.

 

8.6 Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.
Neither the Company nor any Investor shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other.

 

8.7 Public
Disclosures. The Company shall on or before 8:30 a.m., New York time, within four Business Days after the date of this Agreement,
file a Current Report on Form 8-K describing all the material terms of the transactions contemplated by the Transaction Documents
in the form required by the 1934 Act and attaching all the material Transaction Documents (including, without limitation, this
Agreement (and all schedules to this Agreement) (including all attachments, the “8-K Filing”).

 

8.8
 Binding Effect; Benefits. This Agreement and all the provisions hereof shall
be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns; nothing
in this Agreement, expressed or implied, is intended to confer on any persons other than the parties hereto or their respective
successors and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

8.9 Amendment;
Waivers. All modifications, amendments or waivers to this Agreement shall require the written consent of each of (i) the Company
and (ii) the Investors owning a majority in principal amount of the Notes.

 

8.10
 Applicable
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving
effect to the conflict of law provisions thereof, and the parties hereto.

 

    12

     

    

 

8.11 Arbitration.
Each Investor and the Company agree that they shall resolve all disputes, controversies and differences which may arise between
them, out of or in relation to or in connection with this Agreement, after discussion in good faith attempting to reach an amicable
solution. Provided that such disputes, controversies and differences remain unsettled after discussion between the parties, both
parties agree that those unsettled matter(s) shall be finally settled by arbitration in New York, New York in accordance with
the latest Rules of the American Arbitration Association. Such arbitration shall be conducted by three arbitrators appointed as
follows: each party will appoint one arbitrator and the appointed arbitrators shall appoint a third arbitrator. If within thirty
(30) days after confirmation of the last appointed arbitrator, such arbitrators have failed to agree upon a chairman, then the
chairman will be appointed by the American Arbitration Association. The decision of the tribunal shall be final and may not be
appealed. The arbitral tribunal may, in its discretion award fees and costs as part of its award. Judgment on the arbitral award
may be entered by any court of competent jurisdiction, including any court that has jurisdiction over either party or any of their
assets. At the request of any party, the arbitration proceeding shall be conducted in the utmost secrecy subject to a requirement
of law to disclose. In such case, all documents, testimony and records shall be received, heard and maintained by the arbitrators
in secrecy, available for inspection only by any party and by their attorneys and experts who shall agree, in advance and in writing,
to receive all such information in secrecy. 

 

8.12
 Further Assurances. Each party hereto shall do and perform or cause to be done
and performed all such further acts and shall execute and deliver all such other agreements, certificates, instruments and documents
as any other party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement
and the consummation of the transactions contemplated hereby. 

 

8.13 Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which
taken together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be
deemed an original.

 

8.14 Independent
Nature of Investors. The obligations of each Investor under this Agreement or other transaction document are several and not
joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations
of any other Investor under this Agreement or any other transaction document. Each Investor shall be responsible only for its
own representations, warranties, agreements and covenants hereunder. The decision of each Investor to purchase Securities pursuant
to this Agreement has been made by such Investor independently of any other Investor and independently of any information, materials,
statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition
(financial or otherwise) or prospects of the Company which may have been made or given by any other Investor or by any agent or
employee of any other Investor, and no Investor or any of its agents or employees shall have any liability to any other Investor
(or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein
or in any other transaction document, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute
the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the
Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by
this Agreement. Except as otherwise provided in this Agreement or any other transaction document, each Investor shall be entitled
to independently protect and enforce its rights arising out of this Agreement or out of the other transaction documents, and it
shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. Each Investor
has been represented by its own separate legal counsel in connection with the transactions contemplated hereby.

 

[Signature
Page to Follow]

 

    13

     

    

 

IN
WITNESS WHEREOF, the undersigned Investors and the Company have caused this Securities Purchase Agreement to be duly executed
as of the date first above written.

 

	ICAGEN, INC.	 
	 	 
	By: 		 
	Name: 	Richard Cunningham	 
	Title:	President and Chief Executive Officer	 

 

INVESTORS:

 

The
Investors executing the Signature Page in the form attached hereto as Annex 1 and Purchaser Questionnaire the form attached
hereto as Annex 2 and delivering the same to the Company or its agents shall be deemed to have executed this Agreement
and agreed to the terms hereof.

 

    14

     

    

 

ANNEX
1

Securities Purchase Agreement

Investor Counterpart Signature Page

 

The
undersigned, desiring to: (i) enter into this Securities Purchase Agreement dated as of August , 2018 (the “Agreement”),
with the undersigned, Icagen, Inc., a Delaware corporation (the “Company”), in or substantially in the form
furnished to the undersigned and (ii) purchase the Units as set forth below, hereby agrees to purchase such Units from the Company
as of the Closing and further agrees to join the Agreement as a party thereto, with all the rights and privileges appertaining
thereto, and to be bound in all respects by the terms and conditions thereof. The undersigned specifically acknowledges having
read the representations in the Agreement section entitled “Representations, Warranties and Acknowledgments of the Investors,”
and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as an Investor.

 

	All
        Investors: 

         

        Address:

         

        Telephone
        No.:

         

        Facsimile
        No.:

         

        Email
Address:
	Name
        of Investor:

         

        If
        an entity: 

         

        Print
        Name of Entity:

         

        _______________________________________

        By:

        Name:

        Title:

         

        If
an individual:

         

        Print Name:

         

        Signature:
        ______________________________

         

        If
        joint individuals: 

         

        Print
        Name: _____________________________

         

        Signature:
______________________________

 

The
Investor hereby elects to purchase            Units at a purchase price of $10,000 per Unit under the Securities Purchase Agreement at a
total Purchase Price of $             .

 

     

     

    

 

Annex
2

 

CONFIDENTIAL
PURCHASER QUESTIONNAIRE

 

THIS
QUESTIONNAIRE MUST BE ANSWERED FULLY AND RETURNED ALONG WITH YOUR COMPLETED SUBSCRIPTION AGREEMENT IN CONNECTION WITH YOUR PROSPECTIVE
PURCHASE OF UNITS FROM ICAGEN, INC. (THE “COMPANY”).

 

THE
INFORMATION SUPPLIED IN THIS QUESTIONNAIRE WILL BE HELD IN STRICT CONFIDENCE. NO INFORMATION WILL BE DISCLOSED EXCEPT TO THE EXTENT
THAT SUCH DISCLOSURE IS REQUIRED BY LAW OR REGULATION, OTHERWISE DEMANDED BY PROPER LEGAL PROCESS OR IN LITIGATION INVOLVING THE
COMPANY AND ITS CONTROLLING PERSONS.

 

Capitalized
terms used herein without definition shall have the respective meanings given such terms as set forth in the Subscription Agreement
between Icagen, Inc. and the subscriber signatory thereto (the “Subscription Agreement”).

 

(1) The
undersigned represents and warrants that he, she or it comes within at least one category marked below, and that for any category
marked, he, she or it has truthfully set forth, where applicable, the factual basis or reason the undersigned comes within that
category. The undersigned agrees to furnish any additional information which the Company deems necessary in order to verify the
answers set forth below.

 

	Category
A __	The
undersigned is an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with his or
her spouse, presently exceeds $1,000,000.

 

Explanation.
In calculating net worth you may include equity in personal property and may include real estate, provided, however, you cannot
include your principal residence), cash, short-term investments, stock and securities. Equity in personal property and real estate
should be based on the fair market value of such property less debt secured by such property.

 

	Category
B __	The
undersigned is an individual (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two
most recent years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case including
foreign income, tax exempt income and full amount of capital gains and losses but excluding any income of other family members
and any unrealized capital appreciation) and has a reasonable expectation of reaching the same income level in the current year.

 

	Category
C __	The
undersigned is a director or executive officer of the Company which is issuing and selling the Shares.

 

	Category
D __	The
undersigned is a bank, as defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the “Act”); a savings
and loan association or other institution as defined in Section 3(a)(5)(A) of the Act, whether acting in its individual or fiduciary
capacity; any insurance company as defined in Section 2(13) of the Act; any investment company registered under the Investment
Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act; any Small Business Investment
Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of
1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state
or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee
benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a
plan fiduciary, as defined in Section 3(21) of such act, which is either a bank, savings and loan association, insurance company,
or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed
plan, with investment decisions made solely by persons that are accredited investors. (describe entity)
	 	 
	 	 
	 	 

 

     

     

    

 

	Category
E __	The
undersigned is a private business development company as defined in section 202(a) (22) of the Investment Advisors Act of 1940.
(describe entity)
	 	 
	 	 
	 	 

 

	Category
F __	The
undersigned is either a corporation, partnership, Massachusetts business trust, or non-profit organization within the meaning
of Section 501(c)(3) of the Internal Revenue Code, in each case not formed for the specific purpose of acquiring the Shares and
with total assets in excess of $5,000,000. (describe entity)
	 	 
	 	 
	 	 

 

	Category
G __	The
undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Shares,
where the purchase is directed by a “sophisticated investor” as defined in Regulation 506(b)(2)(ii) under the Act.
	 	 
	 	 
	 	 

 

	Category
H __	The
undersigned is an entity (other than a trust) in which all of the equity owners are “accredited investors” within
one or more of the above categories. If relying upon this Category alone, each equity owner must complete a separate copy of this
Purchaser Questionnaire. (describe entity)
	 	 
	 	 
	 	 

 

The
undersigned agrees that the undersigned will notify the Company at any time on or prior to the applicable closing in the event
that the representations and warranties in this Purchaser Questionnaire shall cease to be true, accurate and complete.

 

(2) Suitability
(please answer each question)

 

		(a)	For
                                         an individual, please describe your current employment, including the company by which
                                         you are employed and its principal business:
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

    2

     

    

 

		(b)	For
                                         an individual, please describe any college or graduate degrees held by you:
	 	 	 
	 	 	 
	 	 	 

 

		(c)	For
all subscribers, please list types of prior investments:
	 	 	 
	 	 	 
	 	 	 

  

		(d)	For
                                                                                                                                                                                                                                                                                          all subscribers, please state whether you have you participated in other private placements before:

 

Yes
☐                              No ☐

 

		(e)	If
                                         your answer to question (d) above was “YES”, please indicate frequency of
                                         such prior participation in private placements of:

 

	 	 	Public

Companies	 	Private

Companies
	 	Frequently		 	 
	 	Occasionally	 	 	 
	 	Never	 	 	 

 

		(f)	For
                                         individuals, do you expect your current level of income to significantly decrease in
                                         the foreseeable future?

 

Yes
☐                              No ☐

 

		(g)	For
                                         trust, corporate, partnership and other institutional subscribers, do you expect your
                                         total assets to significantly decrease in the foreseeable future?

 

Yes
☐                              No ☐

 

		(h)	For
                                         all subscribers, do you have any other investments or contingent liabilities which you
                                         reasonably anticipate could cause you to need sudden cash requirements in excess of cash
                                         readily available to you?

 

Yes
☐                              No ☐

 

		(i)	For
                                         all subscribers, are you familiar with the risk aspects and the non-liquidity of investments
                                         such as the Shares for which you seek to purchase?

 

Yes
☐                              No ☐

 

    3

     

    

 

		(j)	For
                                         all subscribers, do you understand that there is no guarantee of financial return on
                                         this investment and that you run the risk of losing your entire investment?

 

Yes
☐                              No ☐

 

(3) Manner
in which title is to be held: (circle one)

 

		(a)	Individual
Ownership

 

		(b)	Community
Property

 

		(c)	Joint
Tenant with Right of Survivorship (both parties must sign)

 

		(d)	Partnership

 

		(e)	Tenants
in Common

 

		(f)	Company

 

		(g)	Trust

 

		(h)	Other

 

(4) FINRA
Affiliation.

 

Are
you affiliated or associated with an FINRA member firm (please check one):

 

Yes
☐                              No
☐

 

If
Yes, please describe how you are affiliated/associated:

 

	 
	 
	 

  

*If
subscriber is a Registered Representative with an FINRA member firm, have the following acknowledgment signed by the appropriate
party:

 

The
undersigned FINRA member firm acknowledges receipt of the notice required by the FINRA Conduct Rules.

 

	 	 	 
	 	Name of FINRA Member Firm	 
	 	 	 	 
	 	By:	 	 
	 	 	Authorized Officer	 
	 	 	 	 
	 	Date:	 	 

 

    4

     

    

 

(5)
 For Trust Subscribers

 

A.
Certain trusts generally may not qualify as accredited investors except under special circumstances. Therefore, if you intend
to purchase the Shares of the Company in whole or in part through a trust, please answer each of the following questions.

 

Is
the trustee of the trust a national or state bank that is acting in its fiduciary capacity in making the investment on behalf
of the trust?

 

Yes
☐                              No
☐

 

Does
this investment in the Company exceed 10% of the trust assets?

 

Yes
☐                              No ☐

 

B.
If the trust is a revocable trust, please complete Question 1 below. If the trust is an irrevocable trust, please
complete Question 2 below.

 

1. REVOCABLE
TRUSTS

 

Can
the trust be amended or revoked at any time by its grantors:

 

Yes
☐                              No
☐

 

If
yes, please answer the following questions relating to each grantor (please add sheets if necessary):

 

	Grantor
    Name:	 	 

  

Net
worth of grantor exceeds $1,000,000 (including spouse, if applicable, real estate (excluding personal residence), automobiles,
cash, short-term investments, stock and securities. Equity in personal property and real estate should be based on the fair market
value of such property less debt secured by such property)?

 

Yes
☐                              No
☐

 

OR

 

Income
(exclusive of any income attributable to spouse) was in excess of $200,000 for 2016 and 2017 and is reasonably expected to be
in excess of $200,000 for 2018?

 

Yes
☐                              No
☐

 

OR

 

Income
(including income attributable to spouse) was in excess of $300,000 for 2016 and 2017 and is reasonably expected to be in excess
of $300,000 for 2018?

 

Yes
☐                              No
☐

 

    5

     

    

 

2. IRREVOCABLE
TRUSTS

 

If
the trust is an irrevocable trust, please answer the following questions:

 

Please
provide the name of each trustee:

 

	 	Trustee Name:	 	 
	 	 	 	 
	 	Trustee Name:	 	 

 

Does
the trust have assets greater than $5 million?

 

Yes
☐                              No
☐

 

Do
you have such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of
an investment in the Company?

 

Yes
☐                              No
☐

 

Indicate
how often you invest in:

 

Marketable
Securities

 

Often
☐     Occasionally ☐     Seldom ☐     Never ☐

 

Restricted
Securities

 

Often
☐     Occasionally ☐     Seldom ☐     Never
☐

 

Venture
Capital Companies

 

Often
☐     Occasionally ☐     Seldom ☐     Never
☐

 

(6)
Bad Actor Disqualifications Questions

 

If
all responses to the questions set forth below in this section (6) are no, please check here o

 

		(A)	Have
                                         you been convicted, within 10 years before a sale in the current offering (or 5 years
                                         in the case of issuers, their predecessors and affiliated issuers), of any felony or
                                         misdemeanor:

 

		(i)	In
                                         connection with the purchase or sale of any security?

 

Yes
☐                              No ☐

 

		(ii)	Involving
                                         the making of any false filing with the Securities and Exchange Commission?

 

Yes
☐                              No ☐

 

    6

     

    

 

		(iii)	Arising
                                         out of the conduct of the business of an underwriter, broker, dealer, municipal securities
                                         dealer, investment adviser, or paid solicitor of purchasers of securities?

 

Yes
☐                              No ☐

 

		(B)	Are
                                         you subject to any order, judgment or decree of any court of competent jurisdiction,
                                         entered within five years before such sale, that, at the time of such sale, retrains
                                         or enjoins such person from engaging ort continuing to engage in any conduct or practice:

 

(i) In
connection with the purchase or sale of any security?

 

Yes
☐                              No ☐

 

		(ii)	Involving
                                         the making of any false filing with the Securities and Exchange Commission?

 

Yes
☐                              No ☐

 

		(iii)	Arising
                                         out of the conduct of the business of an underwriter, broker, dealer, municipal securities
                                         dealer, investment adviser, or paid solicitor of purchasers of securities?

 

Yes
☐                              No ☐

 

		(C)	Are
                                         you subject to a final order of a state securities commission (or any agency or officer
                                         of a state performing like functions; a state authority that supervises or examines banks,
                                         savings associations, or credit unions; a state insurance commission (or an agency or
                                         officer of a state performing like functions); an appropriate federal banking agency;
                                         the U. S. Commodity Futures Trading Commission; or the National Credit Union Administration
                                         that:

 

		(i)	At
                                         the time of such sale, bars you from:

 

		●	Association
                                         with an entity regulated by such commission, authority, agency, or officer;

 

		●	Engaging
in the business of securities, insurance or banking; or

 

		●	Engaging
in savings association or credit union activities.

 

Yes
☐                              No ☐

 

		(ii)	Constitutes
                                         a final order based on a violation of any law or regulation that prohibits fraudulent,
                                         manipulative, or deceptive conduct entered within 10 years before the sale of the contemplated
                                         transaction.

 

Yes
☐                              No ☐

 

    7

     

    

 

		(D)	Are
                                         you currently subject to an order of the Securities and Exchange Commission entered into
                                         pursuant to section 15(b) or 15B(c) of the Securities Exchange Act of 1934 or Section
                                         203(e) or (f) of the Investment Advisers Act of 1940 which:

 

		(i)	Suspends
                                         or revokes your license as a broker, dealer, municipal securities dealer, or investment
                                         adviser?

 

Yes
☐                              No ☐

 

(ii) Places
limitations on your activities, functions or operations?

 

Yes
☐                              No ☐

 

		(iii)	Bars
                                         you from being associated with any entity or from participating in the offering of any
                                         penny stock?

 

Yes
☐                              No ☐

 

		(E)	Are
                                         you subject to any order of the Securities and Exchange Commission entered within 5 years
                                         before such sale that, at the time of such sale, orders you to cease and desist from
                                         committing or causing a violation or future violation of:

 

		(i)	Any
                                         scienter-based (intent/knowledge based) anti-fraud provision of the federal securities
                                         laws, including, without limitation, section 17(a)(1) of the Securities Act of 1933,
                                         section 10(b) of the Securities Exchange Act of 1934, and 240.10b-5, section 15(c)(1)
                                         of the Securities Exchange Act of 1934 and section 206(1) of the Investment Advisers
                                         Act of 1940, or any other related rule or regulation?

 

Yes
☐                              No ☐

 

		(ii)	Section
                                         5 of the Securities Act of 1933?

 

Yes
☐                              No ☐

 

		(F)	Are
                                         you suspended from membership in, or suspended or barred from association with a member
                                         of, a registered national securities exchange or a registered national or affiliated
                                         securities association for any act or omission to act constituting conduct inconsistent
                                         with just and equitable principles of trade?

 

Yes
☐                              No ☐

 

		(G)	Have
                                         you filed (as either a registrant or an issuer), or named as an underwriter in, any registration
                                         statement or Regulation A offering statement filed with the Securities and Exchange Commission
                                         that, within 5 years before such sale, were you the subject of a refusal order, or stop
                                         order, or order suspending the Regulation A exemption, or is, at the time of such sale,
                                         the subject of an investigation or proceeding to determine whether a stop order or suspension
                                         order should be issued?

 

Yes
☐                              No ☐

 

		(H)	Are
                                         you the subject to an United States Postal Service false representation order within
                                         the last 5 years, or are you, at the time of any sale of the securities offered, subject
                                         to a temporary restraining order or preliminary injunction with respect to conduct alleged
                                         by the United States Postal Service to constitute a scheme or device for obtaining money
                                         or property through the mail by means of false representations.

 

Yes
☐                              No ☐

 

[Remainder
of page intentionally left blank]

 

    8

     

    

 

The
undersigned has been informed of the significance to the Company of the foregoing representations and answers contained in this
Confidential Purchaser Questionnaire and such representations and answers have been provided with the understanding that the Company
will rely on them.

 

	 	 	 	 	Individual
	 	 	 	 	 
	Date:	 	 	 	 
	 	 	 	 	Name of Individual
	 	 	 	 	(Please type or print)
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Signature of Individual
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Name of Joint Owner
	 	 	 	 	(Please type or print)
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Signature (Joint Owner)
	 	 	 	 	 
	 	 	 	 	Partnership, Corporation or
	 	 	 	 	Other Entity
	 	 	 	 	 
	Date:	 	 	 	 
	 	 	 	 	Print or Type Entity Name
	 	 	 	 	 
	 	 	 	By:	 
	 	 	 	 	 
	 	 	 	Name:	 
	 	 	 	 	Print or Type Name
	 	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Signature
	 	 	 	 	 
	 	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Signature (other authorized signatory)

 

    9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]